Neurofibromatosis is a genetic disorder of the nervous system. It mainly affects growth of nerve cells. It is characterized by the growth of tumors on nerves. Neurofibromatosis is considered as a hereditary disease which mainly occurs in children or it can happen due to mutation (change) of genes. Usually the Neurofibromatosis tumors are benign, but sometimes they can become cancerous. There are three types of neurofibromatosis: Type 1 (NF1), Type 2 (NF2), and Schwannomatosis. All three types show varied symptoms.
Market Dynamics
The increasing focus of pharma and biotech companies on the research and development of novel treatment drugs for neurofibromatosis is expected to drive the neurofibromatosis treatment drugs market growth during the forecast period. For instance, on July 8, 2020, Nobelpharma initiated phase 3 clinical trial study to evaluate the safety and efficacy of long-term treatment with NPC-12G gel for patients with neurofibromatosis type I. The study is estimated to complete in April 30, 2022.
Key features of the study:
- This report provides in-depth analysis of the global neurofibromatosis treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neurofibromatosis treatment drugs market based on the following parameters – company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key company covered as a part of this study includes AstraZeneca
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global neurofibromatosis treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurofibromatosis treatment drugs market.
Detailed Segmentation:
- Global Neurofibromatosis treatment drugs market, By Disease Type:
- Neurofibromatosis 1 (NF1)
- Neurofibromatosis 2 (NF2)
- Schwannomatosis
- Global Neurofibromatosis treatment drugs market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Neurofibromatosis treatment drugs market, By Region:
- North America
- By Disease Type:
- Neurofibromatosis 1 (NF1)
- Neurofibromatosis 2 (NF2)
- Schwannomatosis
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Disease Type:
- Neurofibromatosis 1 (NF1)
- Neurofibromatosis 2 (NF2)
- Schwannomatosis
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Disease Type:
- Neurofibromatosis 1 (NF1)
- Neurofibromatosis 2 (NF2)
- Schwannomatosis
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Disease Type:
- Neurofibromatosis 1 (NF1)
- Neurofibromatosis 2 (NF2)
- Schwannomatosis
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Disease Type:
- Neurofibromatosis 1 (NF1)
- Neurofibromatosis 2 (NF2)
- Schwannomatosis
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Disease Type:
- Neurofibromatosis 1 (NF1)
- Neurofibromatosis 2 (NF2)
- Schwannomatosis
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profile
-
- AstraZeneca *
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
“*” marked represents similar segmentation in other categories in the respective section.
